In the BioHarmony Drug Report Database

"Preview" Icon

Lapatinib

Tykerb, Tyverb (lapatinib) is a small molecule pharmaceutical. Lapatinib was first approved as Tykerb on 2007-03-13. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against epidermal growth factor receptor and receptor tyrosine-protein kinase erbB-2. Tykerb’s patent is valid until 2029-09-18 (FDA).

 

Trade Name

 

Tyverb
 

Common Name

 

lapatinib
 

ChEMBL ID

 

CHEMBL554
 

Indication

 

breast neoplasms
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Lapatinib structure rendering